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Independent Validation of Six Melanoma Risk
Prediction Models
Catherine M. Olsen1, Rachel E. Neale1, Ade`le C. Green1,2, Penelope M. Webb1, the QSkin Study1,
the Epigene Study1 and David C. Whiteman1
Identifying people at high risk of melanoma is important for targeted prevention activities and surveillance.
Several tools have been developed to classify melanoma risk, but few have been independently validated. We
assessed the discriminatory performance of six melanoma prediction tools by applying them to individuals from
two independent data sets, one comprising 762 melanoma cases and the second a population-based sample of
42,116 people without melanoma. We compared the model predictions with actual melanoma status to measure
sensitivity and specificity. The performance of the models was variable with sensitivity ranging from 97.7 to 10.5%
and specificity from 99.6 to 1.3%. The ability of all the models to discriminate between cases and controls,
however, was generally high. The model developed by MacKie et al. (1989) had higher sensitivity and specificity
for men (0.89 and 0.88) than women (0.79 and 0.72). The tool developed by Cho et al. (2005) was highly specific
(men, 0.92; women, 0.99) but considerably less sensitive (men, 0.64; women, 0.37). Other models were either
highly specific but lacked sensitivity or had low to very low specificity and higher sensitivity. Poor performance
was partly attributable to the use of non-standardized assessment items and various differing interpretations of
what constitutes ‘‘high risk’’.
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INTRODUCTION
Accurate identification of people at high risk of melanoma is
important for both prevention and early detection. In terms of
medical surveillance, although the efficacy of routine skin
screening in people of average risk remains unproven (Geller,
2002; Wolff et al., 2009), there is some evidence that
screening those at high risk of melanoma is cost-effective
(Freedberg et al., 1999) and may improve survival (MacKie
et al., 1993). Medical organizations in North America
(Feightner, 1994; Wolff et al., 2009), New Zealand, and
Australia (ACNMGRW, 2008) recommend screening subsets
of the population determined to be at high risk. A number of
tools have been developed to assist this targeted screening, but
recent reviews (Usher-Smith et al., 2014; Vuong et al., 2014)
reported that only one (Fortes et al., 2010) had been externally
validated in a new population, an important step to assess the
performance of a model (Altman et al., 2009).
Models tend to perform better when the distributions
of melanoma risk factors in the new population are within
the ranges seen in the development population (Moons et al.,
2009). To assess the validity of a risk model in an indepen-
dent population, one first calculates a risk score for the
individuals in the new population using the parameters from
the specified risk model. These risk scores are then compared
with the actual status of each individual to assess how
well the model discriminates those with the condition from
those without. There are three different elements of validity: (i)
agreement between the observed and predicted probabili-
ties of outcomes (calibration), (ii) ability to distinguish
subjects with different outcomes (discrimination), and (iii)
ability to improve the decision-making process (clinical
usefulness). We assessed the performance of six melanoma
risk prediction tools, applying the risk metrics defined by the
model developers, using two independent Australian data sets:
a series of melanoma patients (the Epigene Study (Kvaskoff
et al., 2013)) and a large population-based sample of people
without melanoma (controls; the QSkin Study (Olsen et al.,
2012)).
RESULTS
Table 1 shows a summary of the risk prediction models.
The number of variables included in the models ranged
from 4 to 10. Only one model developed in an Italian
population had been externally validated (in a Brazilian
population; Fortes et al., 2010). Two other models were
developed in US populations (Cho et al., 2005; Fears et al.,
2006) and one each in Australian (Mar et al., 2011), Scottish
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(MacKie et al., 1989), and French (Quereux et al., 2011)
populations.
Study design
Of the six tools, four were developed from case-control
studies (MacKie et al., 1989; Fears et al., 2006; Fortes et al.,
2010; Quereux et al., 2011), one from a prospective
cohort study (Cho et al., 2005), and one using relative risks
from meta-analyses of published data and attributable risk
estimates from a clinical series of melanoma patients (Mar
et al., 2011).
Definition of risk metrics
Two risk prediction models used arbitrary absolute risk cut-
points, defining ‘‘high risk’’ individuals as those with a 5-year
absolute risk greater than 0.15% (Fears et al., 2006; Mar et al.,
2011). One model (Fortes et al., 2010) defined ‘‘high risk’’
individuals using cut-off points on the receiver operating
characteristic (ROC) curve to maximize sensitivity and
specificity. For another model (Quereux et al., 2011), a
‘‘high risk’’ individual was defined as having three or more
risk factors present or one major risk factor (‘‘presence of more
than 20 nevi on the arms’’ for people aged below 60 years and
Table 1. Characteristics of six melanoma risk prediction models
Author (year of
publication)
Geographic
location Study design Model predictors Risk metrics
Mar et al., 2011 Australia Published
meta-analysis
and registry data
Age
Sex
State
Total common nevi
Atypical nevi
Freckles
Hair color
Family history of melanoma
Personal history of melanoma
Personal history of keratinocyte
cancer
5-year risk (%):
Very high, 43%;
High, 0.15%;
Moderate, 40.045%;
Low
Quereux et al., 2011 France Case-control Age
Sex
Nevi on arms
Freckles
Family history of melanoma
Severe sunburn in childhood
Skin phototype
Life in a country at low latitude
High risk defined as having three or more
risk factors or one major risk factor.
Fortes et al., 2010 Italy Case-control Common nevi
Skin color
Hair color
Freckles
Sunburns in childhood
Score of 3 or more.
High risk defined by using cut-off points
on the receiver operating characteristic
curve to maximize sensitivity and
specificity
Fears et al., 2006 USA Case-control Age
Sex
Region
Small nevi
Large nevi1
Freckling
Light complexion
Skin photototype
Light or no tan
Severe solar damage1
5-year risk (%):
Very high, 43%;
High, 0.15%;
Moderate, 40.045%;
Low
Cho et al., 2005 USA Prospective
cohort
Age
Sex
Nevi 43 mm on arms/legs
Hair color
Family history of melanoma
History of severe sunburn
10-year risk (%)
Risk cut-points not defined
MacKie et al., 1989 Scotland Case-control Sex
Total nevi
Atypical nevi
Freckling tendency
Relative Risk:
o2¼ low or average risk;
2–5¼ increased risk;
5–10¼ greatly increased risk;
410¼ very greatly increased risk
1Men only.
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‘‘presence of freckles’’ for patients aged 60 years and above).
The fifth model defined ‘‘very high risk’’ individuals as those
with a relative risk over 10 (MacKie et al., 1989). The sixth
model by Cho et al. (2005) did not define risk cut-points.
Characteristics of the case (Epigene) and control (QSkin)
populations are provided in Supplementary Tables 1 and 2,
online respectively. The mean age of cases was 58 years and
controls 56 years.
Sensitivity, specificity, and area under the ROC curve
The performance of the models in the validation data sets
using the thresholds defined by the original investigators was
variable. Sensitivity of the models ranged from 0.98 to 0.11
and specificity from 1 to 0.01. The model developed by
MacKie et al. (1989) had higher sensitivity for men than
women (0.89 and 0.79, respectively) and also higher
specificity (0.88 and 0.72 ; Table 2). The tool developed by
Cho et al. (2005) was highly specific (0.92 for men; 0.99 for
women) but less sensitive (0.64 for men; 0.37 for women).
Other models were either highly specific (Mar et al., 2011) but
lacked sensitivity or had low (Quereux et al., 2011) to very
low specificity (Fears et al., 2006; Fortes et al., 2010) and
higher sensitivity.
It is notable that two models categorized a large proportion
of both cases and controls as high risk (Fears et al., 2006;
Fortes et al., 2010), whereas two others had high specificity
but lower sensitivity, correctly identifying a large proportion of
controls as low risk (Cho et al., 2005; Mar et al., 2011).
Factors contributing to these outcomes included the risk
factors included in the models (Table 1), the magnitude of
the risks ascribed to those factors (Supplementary Tables 3–8
online), and the prevalence of those risk factors in the two
independent populations (Supplementary Tables 1–2 online).
For the model by Fortes et al. (2010), the median risk scores in
the case and control data sets were 218 and 42, respectively,
but using the authors’ defined cut-point of 3 placed a large
proportion of both cases and controls in the high risk category.
Similarly, for the model by Fears et al. (2006), the mean
estimate of 5-year melanoma risk was 0.49 and 0.71 in the
control and case data sets, respectively, with a cut-point for
high risk of 0.15. Conversely, the model by Mar et al. (2011)
correctly classified 99% of controls as low risk but showed
lower sensitivity; the median 5-year melanoma risk was 0.006
in the control data set and 0.08 in the case data set (again with
a cut-point for high risk of 0.15).
Stratification by age showed that the models by Quereux
et al. (2011) and MacKie et al. (1989) were more sensitive for
people aged o60, whereas the model by Cho et al. (2005)
was more sensitive among those aged Z60 years (Supple-
mentary Table 9 online). Model specificity did not vary widely
between the two age-groups. There were no appreciable
differences in the model performance for men and women
separately (data not shown).
Using a common threshold of specificity, the model with
the highest sensitivity was the model by Mar et al, 2011;
(Table 3), followed by the models of Cho et al. (2005), MacKie
et al. (1989), and Fortes et al. (2010). The model by Fears et al.
(2006) had the lowest sensitivity at thresholds of 80 and 90%
specificity; this model included a measure of ‘‘severe solar
damage’’ to the skin (for men only), which was not available
in the Epigene or QSkin data sets.
Overall, the discriminatory performance of the models was
high, with area under the curve (AUC) values ranging from
0.73 (95% confidence interval (CI) 0.71–0.75) for the model
by Fears et al. (2006) to 0.93 (95% CI 0.92–0.95) for the
model by Mar et al. (2011); Table 2; Figure 1). For the two
models that had presented AUC values for their model
derivation data sets, the AUC values were slightly higher in
our validation data set (0.80 vs. 0.71 for the model by
Quereux et al. (2011) and 0.89 vs. 0.79 for the model by
Fortes et al. (2010)).
Calibration
When the Hosmer–Lemeshow goodness-of-fit test was used to
quantify the overall fit of the models to the data, a high P-
value for the model developed by MacKie et al. (1989;
P¼0.99) indicated an excellent agreement between the
observed and the expected number of cases; for all other
models, the P-value was o0.001. The calibration curves are
presented as Figure 2.
Table 2. Sensitivity, specificity, and receiver operating characteristic curve areas (AUC) of six melanoma risk
prediction models tested in two independent data sets
Risk prediction model
Sensitivity Specificity AUC ROC (95% CI)
Males Females Males Females Males Females Persons
Mar et al., 2011 0.36 0.11 0.99 0.99 0.96 (0.95–0.97) 0.89 (0.86–0.91) 0.93 (0.92–0.95)
Quereux et al., 2011 0.62 0.84 0.60 0.47 0.81 (0.79–0.83) 0.82 (0.79–0.85) 0.80 (0.78–0.81)
Fortes et al., 2010 1 1 0.01 0.01 0.91 (0.89–0.92) 0.88 (0.86–0.90) 0.89 (0.88–0.90)
Fears et al., 2006 0.98 0.79 0.12 0.21 0.82 (0.80–0.84) 0.47 (0.43–0.50) 0.73 (0.71–0.75)
Cho et al., 20051 0.64 0.37 0.92 0.99 0.93 (0.92–0.94) 0.90 (0.88–0.91) 0.92 (0.91–0.93)
MacKie et al., 19892 0.89 0.79 0.88 0.72 0.92 (0.89–0.92) 0.79 (0.77–0.81) 0.85 (0.84–0.86)
Abbreviations: AUC, area under the curve; CI, confidence interval; ROC, receiver operating characteristic curve.
1calculated 5-year risk and using the same cut-point (0.15%) as the Mar and Fears models.
2very greatly increased risk (RR410).
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Classification accuracy
When the accuracy of each model was assessed for
classifying participants’ risks of melanoma according to
categories as defined by the authors (Table 4), results
differed substantially. Although the models by MacKie et al.
(1989), Fears et al. (2006), and Fortes et al. (2010) correctly
assigned high or very high risk classifications to more
than 90% of melanoma cases, the latter two also assigned
similarly high classifications to more than 80% of population
controls.
Sensitivity analyses
We repeated the analyses replacing ‘‘facial freckling’’ with
‘‘shoulder freckling’’ in the evaluation of the models by
MacKie et al. (1989), Fears et al. (2006), Quereux et al.
(2011), and Fortes et al. (2010)); these models all included
‘‘presence of freckling’’ with the exception of Fears et al.
(2006) who included ‘‘freckling on the back’’. This substitu-
tion decreased the sensitivity of the model by MacKie et al.
(1989; from 0.79 to 0.58 for women and from 0.89 to 0.82 for
men), increased the sensitivity of the model by Fears et al.
(2006) for women only (from 0.79 to 0.86) and the model by
Quereux et al. (2011; from 0.84 to 0.96 for women and from
0.62 to 0.85 for men), and made no change to the sensitivity
of the model by Fortes et al. (2010).
Using alternative skin phototype variables (burning/tanning)
in lieu of skin color made no appreciable difference to the
sensitivity or specificity of the models by Fears et al. (2006)
and Fortes et al. (2010; data not presented). Substituting a
tanning variable in place of a burning variable for skin type
increased the sensitivity and specificity of the model by
Quereux et al. (2011; sensitivity 0.95 for women and 0.83
for men; specificity 0.56 for women and 0.68 for men).
Substituting these alternate variables in the ROC analyses
did not materially change the AUC for any of the risk pre-
diction models.
DISCUSSION
There has been increasing interest in developing risk predic-
tion tools to assess disease risk and prognosis. Models
predicting risks of common cancers have been developed
(Freedman et al., 2005), including for cancers of the breast
(Gail et al., 1989), colorectum (Imperiale et al., 2003), prostate
(Eastham et al., 1999), and lung (Spitz et al., 2007). They have
been reasonably successful at identifying groups at higher and
lower risks of developing cancer but have, in general, shown a
limited ability to accurately discriminate between those who
do and do not develop cancer. Our analyses suggest that,
when using the cut-points defined by the model developers,
the sensitivity and specificity of published melanoma risk
prediction models are relatively low when tested in
independent samples. This indicates that the models were
poorly calibrated for predicting melanoma risk in the
Australian population; however, the ability of the models to
Table 3. Sensitivity of six melanoma risk prediction
models tested in two independent data sets using two
different thresholds of specificity
Risk prediction
model
Sensitivity at
80% specificity
Sensitivity at
90% specificity
Mar et al., 2011 0.89 0.81
Quereux et al., 2011 0.64 0.51
Fortes et al., 2010 0.83 0.66
Fears et al., 2006 0.54 0.41
Cho et al., 2005 0.86 0.76
MacKie et al., 1989 0.81 0.70
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Figure 1. Receiver operating characteristic (ROC) curve and corresponding
area under the curve (AUC) statistics for the risk score of six melanoma risk
prediction models in the validation cohort.
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Figure 2. Calibration plots for six melanoma risk prediction models in the
validation cohort.
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discriminate between cases and controls was generally high in
our combined data sets.
Published melanoma risk prediction models are heteroge-
neous in terms of the design of the studies used to develop the
models, how predictor variables were defined and included,
and how patients at ‘‘high risk’’ were categorized and defined.
Our sensitivity analyses demonstrate the impact of using
slightly different predictor variables on the sensitivity and
specificity of some models. The variation in model perfor-
mance seen after apparently subtle changes in terms under-
scores the need to establish standardized definitions of these
characteristics across studies.
In evaluating the performance of the models, we considered
the trade-off between sensitivity and specificity. As we were
interested in each model’s capacity to stratify people into
clinically relevant risk categories, models that placed more
people at the extremes of the risk distribution would have the
advantage of facilitating decision-making around targeted
surveillance (with fewer people in the ‘‘middle’’ categories
where there may be uncertainty about the appropriate advice).
The model with the highest sensitivity and specificity
when applied to our data sets using the cut-points defined
by the model developers was the model by MacKie et al.
(1989), developed in a case-control study and incorporating
only four variables (sex, total nevi, atypical nevi, and freckling
tendency). The next best performing models were those
developed by Cho et al. (2005) and Quereux et al. (2011),
although the model by Cho et al. (2005) was more sensitive
among men than women. The model by Cho et al. (2005) was
developed in a large prospective study and included ten
variables, whereas the model by Quereux et al. (2011), with
eight predictor variables, was developed in a case-control
study. In evaluating the differential performance of these
models in our data sets, it was difficult to disentangle the
independent effects of the inclusion/exclusion of risk factors in
the model and their effect sizes. In general, the highest relative
risks reported were for high nevus counts, both common and
atypical (Supplementary Tables 3–8 online).
The discriminatory ability of the melanoma risk prediction
models in our combined data set was generally high with AUC
between 0.73 and 0.93. To put these findings in the context of
models for other cancers, a recent meta-analysis reported a
summary C statistic (equivalent to the AUC in ROC analyses)
for the most well-known model for predicting risk of breast
cancer, the model by Gail et al. (1989). Pooling five
independent validations for the Gail-2 model resulted in a
summary C statistic of 0.63 (95% CI 0.59–0.67; Meads et al.,
2012). Values between 0.6 and 0.8 are also standard for risk
prediction tools in chronic disease (Freedman et al., 2005).
Notable findings of our evaluation of melanoma risk
prediction tools were the marked between-study heterogeneity
in the sources and collection of data, the factors considered for
inclusion in the models, the categorization of these risk
factors, and the choice of analytic model. Strengths of our
analyses include the large sample size of our case and control
groups. All cases were histologically confirmed. Limitations
include possible misclassification of some exposures as a
result of the harmonization of risk factor data. Our melanoma
case group included only melanomas of the trunk, head, and
neck and did not include cases with melanoma on the limbs.
If the risk profile of people with limb melanomas differed
greatly from that of other body sites our evaluation of the
discriminatory accuracy of the prediction models may be
inaccurate, but evidence suggests that this is not the case
(Green and Siskind, 2012).
We did not evaluate risk prediction models that incorpo-
rated genetic predictors as such data were not available for
our validation data sets. Potentially, incorporating genetic
information into risk prediction models could identify people
as high risk who might not be so identified on the basis of their
phenotypes or exposures alone, although evidence for this is
conflicting. Several studies have reported that including the
terms for genotype in addition to the core predictive factors
gave no useful improvement in prediction (Bishop et al., 2009;
Stefanaki et al., 2013), whereas another reported that includ-
Table 4. Classification accuracy of six melanoma risk
prediction models tested in two independent data sets
using cut-points as defined by the model developers
Risk prediction model
Melanoma cases Population controls
Males
(%)
Females
(%)
Males
(%)
Females
(%)
Mar et al., 2011
Low risk 28.0 55.7 96.3 96.9
Moderate risk 36.0 33.9 3.3 2.7
High risk 36.0 10.5 0.4 0.4
Very high risk 0 0 0 0
Quereux et al., 2011
Not at high risk 38.1 15.9 60.5 46.7
High risk 61.9 84.1 39.5 53.3
Fortes et al., 2010
Not at high risk 0 0 1.3 1.3
High risk 100 100 98.7 98.7
Fears et al., 2006
Low risk 0 2.7 0 1.5
Moderate risk 2.3 18.7 13.2 19.1
High risk 89.4 78.7 85.1 79.1
Very high risk 8.4 0 1.7 0.3
Cho et al., 2005
Low risk 0.8 7.0 46.7 66.4
Moderate risk 35.5 55.7 45.5 32.2
High risk 63.7 37.3 7.8 1.4
Very high risk 0 0 0 0
MacKie et al., 1989
Low or average risk 4.5 8.2 39.8 31.8
Increased risk 4.0 7.8 17.4 37.4
Greatly increased risk 2.8 5.0 30.8 3.0
Very greatly increased risk 88.8 79.0 12.1 27.8
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ing MC1R genotype information did convey information about
melanoma risk beyond phenotype (Kanetsky et al., 2010). A
recent study found that including information about MC1R
and previously unreported common genomic variants
increased the predictive capacity of the model by 17% over
the nongenetic model (Cust et al., 2014).
In summary, a large number of prediction models have
been developed for melanoma, ostensibly to aid clinicians
(and their patients) to quantify individual risk and develop
appropriate management plans. To be useful, a prediction tool
must be accurate, generalizable, and clinically effective (Reilly
and Evans, 2006). We found that most existing melanoma
prediction models were poorly calibrated, at least when the
models were applied to an independent Australian data set
using the originally published cut-off scores to estimate risk.
However, most models identified higher proportions of
melanoma cases compared with disease-free controls across
the range of all possible cut-off scores and thus had reasonable
discriminatory accuracy. These findings suggest that models
need to be calibrated specifically for target populations, using
population-specific cut-off scores, before they can be used in
clinical practice. We therefore echo the plea for more efforts
to validate risk prediction tools and encourage the adoption of
reproducible, standardized measures of predictor variables
that can be easily recorded in the clinical setting (Usher-Smith
et al., 2014).
MATERIALS AND METHODS
Melanoma risk prediction tools
We included six melanoma risk prediction models (MacKie et al.,
1989; Cho et al., 2005; Fears et al., 2006; Fortes et al., 2010;
Mar et al., 2011; Quereux et al., 2011) identified from the
recent systematic review (Vuong et al., 2014) that incorporated
variables for which we had equivalents in our data sets. We did
not include models using genetic information (Smith et al., 2012;
Stefanaki et al., 2013) or those that provided insufficient information
to undertake external validation (English and Armstrong, 1988;
Marrett et al., 1992; Garbe et al., 1994; Barbini et al., 1998; Landi
et al., 2001; Harbauer et al., 2003; Fargnoli et al., 2004; Whiteman
and Green, 2005; Goldberg et al., 2007; Williams et al., 2011;
Guther et al., 2012).
Validation populations
Epigene. The Epigene data set included information for 762
incident cases of first primary melanoma diagnosed between 1
April 2007 and 30 September 2010. The methods of this
case–case study have been described previously (Kvaskoff et al.,
2013). All cases were aged 18–79 years and were residents of the
greater Brisbane region, Queensland, Australia. Cases were
ascertained prospectively through pathology companies servicing
the region. The study did not recruit patients with melanomas on
the limbs. Participants completed a detailed questionnaire and
underwent a clinical examination by a dermatologist. The ques-
tionnaire captured information about demographic, phenotypic,
medical, and other risk factors including sun exposure history.
The clinical examination recorded hair and eye color and
numbers of solar keratoses and melanocytic nevi present across
all body sites.
QSkin. The QSkin Study comprises a cohort of 43,781 men and
women aged 40–69 years randomly sampled from the population
of Queensland, Australia, in 2011 (Olsen et al., 2012; overall
participation fraction 23%). At baseline, information about
demographic items, general medical history, standard pigmen-
tary characteristics (including hair and eye color, freckling
tendency, tanning ability and propensity to sunburn), past and
recent history of sun exposure and sunburns, sun protection
behaviors, use of tanning beds, and history of skin cancer was
collected by self-completed questionnaire. Participants gave their
consent for data linkage to cancer registries ensuring complete
ascertainment of all melanoma occurrences (notification of
cancer to Australian Cancer Registries has been legally mandated
since 1982). For these analyses, we restricted the data set to
42,116 participants with no prior history of melanoma.
Data harmonization. We matched variables from the Epigene
and QSkin data sets (the ‘‘validation datasets’’) as closely as
possible to those described in each model (‘‘derivation dataset’’,
Supplementary Tables 3–8 online), irrespective of their later
performance in the model. Where more than one variable in
the validation data sets was a possible match for the correspond-
ing variable from the derivation data set, we performed sensitivity
analyses using the alternative variables. For example, in the
Epigene data set, we had two freckling variables. In our primary
analyses, we used the categorical measures of freckling on the
face but performed sensitivity analyses using freckling on the
shoulders. For skin phototype, both the Epigene and QSkin data
sets included separate variables for tanning and burning
responses. Where skin phototype was included in the model,
we used burning response for our primary analyses, but we
performed sensitivity analyses using the variable for tanning
response. The Epigene data set did not include a variable for
skin color, and we instead used burning response performing
sensitivity analyses using tanning response.
Statistical analyses
For each risk prediction tool, we applied the fully specified model
and calculated a risk score for each person in the two validation data
sets, applying the risk metrics (as defined by the model developers) to
classify people into risk categories (Supplementary Appendix 1
online). We then compared these predictions with actual outcomes,
examining sensitivity in the melanoma cases (Epigene data set) and
specificity in the disease-free controls (QSkin data set). For each
analysis, we excluded individuals with missing data for one or more
predictor variables. The number excluded varied depending upon the
variables specified in each model and ranged from 18% (model by
Quereux et al. (2011)) to 34% (model by Mar et al. (2011)). We
conducted these analyses for all study participants and also stratified
by age (o60/X60 years); 48% of cases and 65% of controls were
aged o60 years.
We examined the classification accuracy of each model using
categories as defined by the authors of each model. For the single
model that did not define a high risk cut-point (Cho et al., 2005), we
defined a 5-year absolute risk greater than 0.15% as high risk to be
consistent with two other models (Fears et al., 2006; Mar et al., 2011).
We investigated reasons for high and low sensitivity and specificity by
examining factors included in the models, their effect sizes, and the
prevalence of those risk factors in the two independent populations.
CM Olsen et al.
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Our calculations of sensitivity and specificity were dependent upon
the choice of cut-point used to define ‘‘high risk’’ by each model. We
also calculated the sensitivity of each model using a common
threshold of specificity (80 and 90%). Area under the ROC curve is
a plot of (1-specificity) of a test against its sensitivity for all possible
cut-off points (Zweig and Campbell, 1993). We therefore combined
the two data sets and evaluated the predictive discrimination of each
model using the area under the ROC curves. We tested the calibration
of each model using the Hosmer–Lemeshow goodness-of-fit test
(Hosmer et al., 1997), where a small P-value indicates departure
from goodness-of-fit. We used SAS PROC LOGISTIC (V.8.02; SAS
Institute, Cary, NC) to calculate the area under the ROC curves.
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